Lithium salts as a treatment for COVID-19: Pre-clinical outcomes.
COVID-19
Inflammation
Lithium
Pre-clinical trial
SARS-CoV-2
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
10
01
2022
revised:
20
03
2022
accepted:
23
03
2022
pubmed:
2
4
2022
medline:
28
4
2022
entrez:
1
4
2022
Statut:
ppublish
Résumé
Identifying effective drugs for Coronavirus disease 2019 (COVID-19) is urgently needed. An efficient approach is to evaluate whether existing approved drugs have anti-SARS-CoV-2 effects. The antiviral properties of lithium salts have been studied for many years. Their anti-inflammatory and immune-potentiating effects result from the inhibition of glycogen synthase kinase-3. To obtain pre-clinical evidence on the safety and therapeutic effects of lithium salts in the treatment of COVID-19. Six different concentrations of lithium, ranging 2-12 mmol/L, were evaluated. Lithium inhibited the replication of SARS-CoV-2 virus in a dose-dependent manner with an IC These results provide pre-clinical evidence of the antiviral and immunotherapeutic effects of lithium against SARS-CoV-2, which supports an advance to clinical trials on COVID-19's patients.
Identifiants
pubmed: 35364381
pii: S0753-3322(22)00261-X
doi: 10.1016/j.biopha.2022.112872
pmc: PMC8947939
pii:
doi:
Substances chimiques
Antiviral Agents
0
Salts
0
Lithium
9FN79X2M3F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112872Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Références
Hum Exp Toxicol. 2020 May;39(5):696-711
pubmed: 31928237
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Front Pharmacol. 2020 Aug 27;11:557629
pubmed: 32973537
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Joint Bone Spine. 2014 May;81(3):240-6
pubmed: 24176738
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Animal Model Exp Med. 2018 Jul 28;1(2):125-133
pubmed: 30891557
Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):351-4
pubmed: 6270956
Avian Pathol. 2007 Apr;36(2):109-14
pubmed: 17479370
J Virol. 2005 Jan;79(1):503-11
pubmed: 15596843
Int Immunopharmacol. 2013 May;16(1):35-40
pubmed: 23542012
Mol Psychiatry. 2002;7(8):845-50
pubmed: 12232777
Immunity. 2016 Feb 16;44(2):274-86
pubmed: 26885856
PLoS One. 2019 Jan 29;14(1):e0209223
pubmed: 30695037
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Acta Pharm Sin B. 2020 May;10(5):766-788
pubmed: 32292689
J Psychopharmacol. 2016 Oct;30(10):1008-19
pubmed: 27307388
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Mol Biomed. 2022 Dec 12;3(1):43
pubmed: 36508083
Pharmacol Ther. 2015 Apr;148:114-31
pubmed: 25435019
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9
pubmed: 8710892
Biomedicines. 2021 Oct 20;9(11):
pubmed: 34829735
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32929051
J Virol. 2005 Mar;79(6):3846-50
pubmed: 15731278
J Med Virol. 2017 Nov;89(11):2041-2046
pubmed: 28390158
Med Microbiol Immunol. 1980;168(2):139-48
pubmed: 6256617
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684
pubmed: 33251966
Cell Host Microbe. 2014 Oct 8;16(4):462-72
pubmed: 25299332
Int Clin Psychopharmacol. 2022 Jan 1;37(1):25-28
pubmed: 34686643
Int J Mol Sci. 2018 Jul 23;19(7):
pubmed: 30041458
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Curr Med Chem. 2020;27(3):337-351
pubmed: 30182841
Antiviral Res. 2014 Mar;103:39-50
pubmed: 24418573
Mol Cell. 2020 Dec 17;80(6):1092-1103.e4
pubmed: 33248025
Cephalalgia. 1983 Jun;3(2):109-14
pubmed: 6409415
J Intern Med. 2018 Feb;283(2):110-120
pubmed: 29071761
Cell Physiol Biochem. 2013;32(6):1720-8
pubmed: 24356466
Mem Inst Oswaldo Cruz. 2021 Feb 08;116:e200443
pubmed: 33566951
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Pharm Stat. 2011 Mar-Apr;10(2):128-34
pubmed: 22328315
Front Immunol. 2020 Jun 26;11:1638
pubmed: 32695123
Int J Nanomedicine. 2019 Sep 12;14:7475-7488
pubmed: 31571859
Sci Rep. 2017 May 31;7(1):2495
pubmed: 28566716
Res Vet Sci. 2018 Jun;118:288-294
pubmed: 29547727
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
PLoS One. 2011 May 06;6(5):e18669
pubmed: 21573100
Science. 2003 May 30;300(5624):1394-9
pubmed: 12730500
Int J Med Sci. 2020 Jul 19;17(13):1964-1973
pubmed: 32788875
EMBO J. 2020 Dec 15;39(24):e106478
pubmed: 33200826
NPJ Vaccines. 2021 Mar 19;6(1):39
pubmed: 33741993
Bipolar Disord. 2007 Nov;9(7):743-53
pubmed: 17988365
Cureus. 2020 May 31;12(5):e8384
pubmed: 32637266
Cell Rep. 2020 Feb 18;30(7):2075-2082.e4
pubmed: 32075731
Front Mol Neurosci. 2011 Nov 16;4:40
pubmed: 22110425
Microb Pathog. 2020 Jul;144:104169
pubmed: 32205210
F1000Res. 2020 Feb 7;9:93
pubmed: 32518634
Cell Rep Med. 2020 Oct 20;1(7):100121
pubmed: 32984855
Oncoimmunology. 2015 Aug 31;5(3):e1085146
pubmed: 27141339
Oncotarget. 2017 Aug 7;8(42):72167-72181
pubmed: 29069777
Avian Pathol. 2009 Jun;38(3):215-21
pubmed: 19468938
Proc Natl Acad Sci U S A. 2021 Oct 19;118(42):
pubmed: 34593624
ILAR J. 2002;43(4):244-58
pubmed: 12391400
Int J Bipolar Disord. 2020 May 20;8(1):21
pubmed: 32435920